Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety, tolerability, and pharmacokinetics of meropenem-vaborbactam in children with complicated urinary tract infection including acute…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Urinary Tract Infection
• Pyelonephritis

Drugs mentioned

• VABOMERE (MEROPENEM-VABORBACTAM)

Snippet

Sponsor: Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | Conditions: Acute Pyelonephritis, Complicated Urinary Tract Infection | Phase 2 | Status: RECRUITING